During stages 2–3 CKD, abnormal biochemical changes in the bones begin, with a rise in FGF- 23 level, and a possible increase in plasma parathyroid hormone (PTH) levels in response to subclinical calcium and phosphate changes. This evidence concerns the gene PTH and chronic kidney disease.